SAFE EFFICACIOUS AUTOLOGOUS TREATMENT OF CLI, PAD, ANGINA, ISCHEMIC & DILATED CARDIOMYOPATHY
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Tech Pi oneer SAFE EFFICACIOUS AUTOLOGOUS TREATMENT OF CLI, PAD, ANGINA, ISCHEMIC & DILATED CARDIOMYOPATHY JAN 2021 © HEMOSTEMIX INC. ALL RIGHTS RESERVED. TSXV:HEM OTC:HMTXF
F O RWA R D -L O O K IN G IN F O R M AT IO N This presentation contains forward looking statements that reflect management’s expectations regarding the future growth and results of operational performance including but not limited to the scientific, financial, competitive and business prospects of Hemostemix Inc. (“Hemostemix” or the “Company”). This Presentation contains “forward-looking statements” and “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information is generally, but not always identified by words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “potential”, “might”, “seek”, “budget ”, “outlook”, and other similar expressions. In addition, forward looking statements include, but are not limited to, the Company’s assessment of and targets for the stem-cell industry, including the potential opportunities and challenges in the current stem cell industry; matters pertaining to Hemostemix, including its strategy and anticipated and potential transactions and the characteristics thereof; future acquisition opportunities, partnerships, licensing opportunities and joint ventures and its pro forma impact to capitalization following the completion of any of the Company 's business opportunities; matters pertaining to the Company’s future research and development initiatives including future clinical trials, management’s estimated timelines regarding the Company’s clinical trials, regulatory approvals for ACP-01 and NCP-01, and many other projected timelines including regulatory approvals of the Company’s submission(s); financial modeling matters, including metrics pertaining to anticipated financial and operational performance of operations; and, any matters pertaining to the potential for commercialization of its technology, sources and extent of necessary funding, manufacturing scalability and future business outcomes. Actual results, performance and achievement (s) could differ materially from that expressed in, or implied by, any forward-looking information in this Presentation and, accordingly, investors should not place undue reliance on any such forward-looking information. Forward-looking information should not be read as guarantees of future performance or results. Forward-looking information and results could differ materially from general business, economic, competitive and regulatory risks now and in the future, including that the Company's current phase II clinical trial will be completed within the timelines and on the terms currently anticipated. As well, results may be inconsistent with general assumptions about the economic environment and stem cell industry environment, the business operations of Hemostemix including that each business will continue to operate in a manner consistent with past practice and pursuant to certain industry expectations and current market conditions. Any forward-looking statements speak only as of the date on which such statement is made and the Company disclaims any intention or obligation to update or revise any forward-looking information as a result of new information, future events or otherwise, unless required by applicable law. New factors emerge from time to time and it is not possible for management to predict how such factors impact the Company’s business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking information contained in this Presentation is based on the Company’s current estimates, expectations and projections, which the Company believes are reasonable as of the current date. The Company can give no assurance that these estimates, expectations and projections will prove to be correct. Historical statements should not be taken as a representation that such trends will be replicated in the future. No statement in this Presentation is intended to be nor may be construed to be an investment recommendation or a profit forecast.
PAT E N T E D A U T O L O G O U S S T E M C E L L T H E R A P Y P L AT F O R M
Hemostemix Inc.
(TSXV:HEM OTC:HMTXF)
>300 Patients treated. 91 patents cover five patent families Ongoing 17 Centre International Phase
Abstract results show improvement in including automated production of II Clinical Trial for Critical Limb
83% of patients tested¹ autologous peripheral blood-based Ischemia
ACP-01 & NCP-01
ACP-01: Studied and clinically trialled for the treatment of ischemia-based conditions of:
Angina
Critical Limb Ischemia and Dilated Cardiomyopathy Future potential : Other
Peripheral Arterial Disease Ischemic Cardiomyopathy Cardiovascular Diseases
¹ Source: Abstract entitled: “Autologous Stem Cell Treatment for CLI Patients w ith No Revascularization Options: An Update of ht e Hemostemix ACP-01 Trial With 4.5 Year Follow up”
H O W S C AL A B L E I S O U R P L AT F O R M ?
H E M O S T E M I X – AT A G L AN C E
Patented Key Partnerships
• 91 Patents issued worldwide
• 5 patent families including automation of • License Negotiations Started
production patent • By Indication by Country
Expandable Platform Data Driven
• ACP-01 – 5 indications • Historical Data >500 patients treated
• NCP-01 - stroke model as an indication • 12 Years of treatment History
• Machine engineered • Multiple Trials (2) and Investigator led
studies (3) completed
Clinical Trials–Clinical Data
• 17 NA Sites : 65th patient enrollment
Optimized Business Plan • Abstract results show 83% of patients (10 of
• Lean structure 12) show improvement
• Experienced board and management team • Endpoints reached Results expected in Q1
2021
• World class Scientific Advisory Board
• International world class Advisory Board
T H E IM P O R TA N C E O F C E L L T H E R A P Y
Disease Trends support need for Strong Government Population and
new therapies and Public support Lifestyle Factors
• CLI is a major global health • Regenerative medicine is the leading • Aging populations worldwide
problem - incidence growing with edge for biotech investment • Good health and quality of life are key
aging population • Unmet need for new less invasive, concerns with aging
• CLI has limited treatment options– less expensive non-surgical
• Poor diet and lifestyle increase
significant amputations and high treatments prevalence of conditions of ischemia -
cost to society • Right to try legislation approved in related diseases treatable with ACP-
• Cardiovascular disease (“CVD”) is the the USA mirrors EU and SE Asia 01.
number one cause of deaths in North autologous conventions of use
America and worldwide causing • There is a gradual shift away from
approximately 1 in 3 deaths drugs toward personalized cell based
• Rising healthcare and economic costs- therapies
CVD costs anticipated to double by 2035
in USA
• Type 2 diabetes is a global health
epidemic on the rise resulting in
increasing PAD and CLI diagnosis
A C P -0 1 D IF F E R E N T IATO R S
Autologous. Proven safety and Blood draw: safer, less invasive Global portfolio of 91 patents
efficacy than fat or bone marrow Including automated production
Non-surgical, enhanced cell therapy treatment for restoring circulation to blood starved tissues and organs
Low Patient Risks High Cell Viability
Self-donation, means no immune Fresh cells in ready-to-use syringes,
rejection or disease transmission no cryopreservation required
Simple Protocol No Ethical Concerns
Safe and easy to perform in Stem cells derived
outpatient clinic directly from patient
No Reported Safety Issues Scalable
No mobilization drugs Simple, cost-effective
needed to collect cells production process
A C P -0 1 P O T E N T IA L M A R K E T S
M U L T I P L E C U R R E N T A N D F U T U R E I N D I C AT I O N S P O T E N T I AL
Critical Limb Ischemia CLI - Tip of the Iceberg
Peripheral Arterial Disease
CLI - Estimated total costs up
to $248B¹ in US.
Angina and CVD
Cardiovascular Disease
Ischemic Renal Disease
In the United States, total
costs of CVD in 2016 was $555B;
Vascular Dementia
it is projected to be $1.1T by 2035
Ischemic Erectile Dysfunction Disease
1Source: The Sage Group
2Source: American Heart Association Report: Cardiovascular Disease: A costly Burden for America
W H Y A C P -0 1 F O R C L I? IT S AV E S L IM B S
Hope for CLI Patients Facing Amputation
01 02
Extract and enrich patient’s Inject patient’s cell population
own cell population from to form new blood vessels,
peripheral blood saving limb
Self-Donor Simple Quick
Uses patient’s own cells, Cell harvest via blood draw 7 days from draw to
no immune rejection, no reinjection into patient’s limb
observed safety issues
C L I W IT H A C P- 0 1 IM PROV E M E NT S V IS UA L IZ E D 47 Days post ACP-01 Treatment Before After
P H A S E II T R IA L F O R C L I U P D AT E
Randomized, placebo-controlled double blind
Phase II clinical trial to confirm the safety and efficacy of ACP-01
US FDA and Health Canada approved trial protocol
Phase II
Trial
CRO All follow-ups completed by Mar
FDA and Health Canada
17 sites on-boarded approved
65th Patient enrolled Multicenter in US and CanadaP H A S E II C L I T R IA L M IL E S TO N E S
H2 2017 H1 2018 H2 2018 H1 2019 H2 2019 H1 2020 H2 2020
Phase II CLI Trial
CRO engaged
Health Canada Approval¹
US FDA Approval²
Site & Patient Recruiting⁴
First Patient Treatment³
Patient Monitoring⁴
Interim Data⁴
Study Completion⁴
A catalyst for future trials
Progression of the CLI Trial has opened the door for other ACP-01 clinical trials
¹Health Canada Phase II Trial continuation approval received in December 2017.
²US FDA Phase II Clinical Trial continuation approval received April 2018.; IND originally approved in August 2015.
³First patient treatment under continued clinical trial announced May 3. 2018.
⁴Anticipated timeline.: April 2021 Report See Forward-Looking Information.A C P -0 1 S T U D Y A N D T R IA L H IS TO RY
Study Number of
Type of Study Study Location Objective of Study Patients Study Status
Design Subjects
Pilot Safety/ To assess the feasibility and safety
Thailand Open label 6 Diagnosed CLI Completed
Feasibility of the implantation
To assess safety or ex vivo expanded,
Completed
Phase 1b Safety peripheral blood-derived, autologous
Hungary Open label 20 Diagnosed PAD And
and Efficacy angiogenic cell precursors (ACPs)
Published
in no option PAD patients
95 (Anticipate
Midpoint
Analysis to be In Progress.
Randomized
completed Enrollment
Phase II Safety Canada and Time to major Double Blind
when 42 Diagnosed CLI suspended
and Efficacy United States amputation/mortality Placebo
patients during Midpoint
Controlled
complete 26 Analysis
weeks of
follow-up)
Clinical Trial Completed
To assess the feasibility and safety of 24 Planned (17
Safety/ Thailand Open label Diagnosed Angina And
intracoronary injection completed)
Feasibility Published
To determine the safety and efficacy of
Diagnosis of severe
intracoronary injection of ACPs in
ischemic heart
relieving symptoms of angina pectoris
Safety and disease with Completed
Thailand and congestive heart failure in chronic Open label 106
Efficacy continued angina Results Available
ischemic heart disease subject with
pain or heart failure
maximal medical therapy and no option
symptoms
for revascularization procedures
INTRAMYOCARDIAL ANGIOGENIC
Diagnosed Ischemic
CELL PERCURSOR INJECTION FOR Completed
Safety and Bangkok Heart Cardiomyopathy or
CARDIOMYOPATHY, Asian Open label 41 And
Efficacy Hospital Dilated
Cardiovascular & Thoracic Annals, 2008, Published
Cardiomyopathy
Vol. 16, No. 2, p 143 - 148,A C P -0 1 S T U D Y A N D A B S T R A C T R E S U LT S ABSTRACT TTLE: AUTOLOGOUS STEM CELL TREATMENT FOR CLI PATIENTS WITH NO REVASCULARIZATION OPTIONS: AN UPDATE OF THE HEMOSTEMIX ACP-01 TRIAL WITH 4.5 YEAR FOLLOW UP Jonathan Misskey MD MHPE¹, Lynn Cunada, RN², Kyle Makofka³, Alan Jacobs MSEE. MD PhD.³, Iris Zhong⁴, Thomas Lindsay MDCM⁴, York N. Hsiang, MB ChB., MHSc., FRCSCS¹ (¹Department of Surgery, UBC, ²Vancouver Coastal Health, ³Hemostemix Inc, ⁴ Division of Vascular Surgery, Peter Munk Cardiac Centre, University Health Network and Department of Surgery, University of Toronto) Results: Twelve patients with CLI and no interventional options were enrolled (10 male, 2 female, mean age 76 years). Prior to treatment with ACP-01 or placebo, 3 patients had ischemic rest pain, 8 patients had ulceration, and one patient had gangrene. Post treatment, one patient with unremitting rest pain and toe gangrene required a below knee amputation, and one patient with gangrene of the first to third toes required a forefoot amputation. Healing of ulcers and resolution of ischemic rest pain occurred in the other 10 (83%) patients. There were no clinically significant safety issues. Outcomes have been maintained for up to 4.5 years (3.5 years for 2 patients, 3 years for 1 and 1 patient died after ulcer healing secondary to congestive heart failure at 6 months). Conclusions: Preliminary long-term results of ACP-01 autologous stem cell treatment in CLI patients with no revascularization options are encouraging. Enrollment in the study is ongoing at medical centers in Canada and the US. We recommend Vascular surgeons to discuss this study with their CLI patients who have no further revascularization options available. Source: AUTOLOGOUS STEM CELL TREATMENT FOR CLI PATIENTS WITH NO REVASCULARIZATION OPTIONS: AN UPDATE OF THE HEMOSTEMIX ACP-01 TRIAL WITH 4.5 YEAR FOLLOWUP
A C P -0 1 S T U D Y A N D A B S T R A C T R E S U LT S
SAFETY AND EFFICACY STUDY - Thailand:
Purpose: To assess the safety and efficacy of transcoronary injection of angiogenic cells precursors (ACPs) in
patients with ischemic cardiomyopathy.
Methods: Between 2005 and 2008, 106 ischemic heart disease patients on maximal medical therapy and no
option for revascularization procedures who underwent transcoronary injection of ACPs at Chaophya hospital,
Bangkok, Thailand were enrolled in the study. This study is a report of case series with non-randomized data
and without control cohort. Follow-up of patients were made mostly by patients' own cardiologists at 2, 4, 6 and
12 months according to the protocol because majority of patients were from abroad.
Results: Baseline study:
• The mean age of 106 patients was 66 ± 10.6 years.
• Majority of patients had Canadian Cardiovascular Society (CCS) class and New York Heart Association
(NYHA) functional class III- IV. Most patients had poor left ventricular systolic function.
• At 1 year follow-up, there was significant improvement of CCS class from 2.63 ± 0.66 to 1.53 ± 0.76 (N = 39, p<
0.001) while NYHA functional class improved from 2.69 ± 0.56 to 1.64 ± 0.83 (N= 32, p< 0.001).
• Post treatment at 2-4 months, patients with poor left ventricular ejection fraction (LVEF ≤40%) at baseline, the LVEF
was increased from34.4% ± 16.4% to 39.1% ± 15.5% (N = 39, p< 0.05).
• The quality of life by SF-36 version 2 Health Survey revealed that General Health and Physical functioning were
significantly improved. Procedural mortality rate was 0%.
Conclusions: Transcoronary injection of ACPs improved cardiac function (increased LVEF), exercise capacity and
quality of life with high safety profile for ischemic cardiomyopathy patients with no-option revascularization.
Source: Transcoronary Injection of Angiogenic Cells Precursors an Autologous Stem Cell in Ischemic Cardiomyopathy: A Clinical study
of 106 cases in Thailand. ASEAN HEART JOURNAL, Vol 17, No. 1, January 2009.A C P -0 1 S T U D Y A N D A B S T R A C T R E S U LT S D IAGNOS E D ANGINA C L INIC AL T RIAL Purpose: To assess the safety and efficacy of intracoronary injection Angiogenic Cell Precursors (“ACP”s) based product for the treatment of patients with chronic stable angina pectoris who were on maximal drug therapy. Methods: Twenty four patients were prospectively enrolled and treated with ACPs. The administration of the therapy was based upon identifying ischemic but viable myocardium (SPECT-MIBI scan) in the distribution of occluded coronary arteries. ACPs were prepared from cells separated from non-mobilized peripheral blood of each patient, cultured ex vivo and injected via a catheter with proximal balloon occlusion of the coronary artery. The patients were assessed clinically pretreatment and at 1, 3 and 6 months after treatment using the following parameters: Canadian Cardiovascular Society (“CCS”) Scale, six minute walk (“6MW”) test, exercise capacity as assessed by metabolic equivalents (“MET”s) and SPECT-MIBI perfusion defect. Preliminary Reported Results: Twenty patients have completed 3 months follow up and 17 have completed 6 months follow up. The clinical condition improved in all patients at 3 and 6 months vs. pretreatment: • 6MW increasing from 333.65±26.56 to 414.95±28.54 meters at 3 months and to 413.25±33.17 meters at 6 months (both P
IN D IC AT IO N P IP E L IN E
Development Phase
Candidate Indication Status
Preclinical Clinical
• Currently 17 sites and 65
ACP-01 • Critical limb ischemia • Phase II clinical trial patients enrolled.
• Trial ongoing
• PAD
• Angina Pectoris
• Ischemic & dilated • Preparing for Phase II Angina
Cardiomyopathy Pectoris trial
ACP-01 • Congestive Heart Disease • Seeking JV partners to fund • Safety trials completed
• Acute Myocardial Infraction phase II trials in each
• Ischemic Renal Disease indication
• Vascular Dementia
• Erectile Dysfunction
• Stroke
• Spinal Cord Injury • Preclinical
NCP-01 • Amyotrophic Lateral • Seeking JV Partners to fund • In R&D
Sclerosis (ALS) trials.
• Bone fractures • Preclinical
BCP-01 • Skeletal breaks • Seeking JV Partners to fund • Preliminary R&D
• Surgical procedures trialsMA NA GE ME NT A ND
DIRECT ORS
Peter Lacey, ICD.D, Chairman of the Board
• Chairman of Cervus Equipment Corporation (CERV.TO), from inception to date.
• President and Chief Executive Officer of Cervus Equipment Corporation and its predecessor entities from 1982 to April 2012.
• Cervus is a company he and his partners started in 1999 and built from five John Deere dealerships to 63 dealerships selling six brands in
three countries with revenues of $1.1 Billion
• Graduate of the Institute of Corporate Directors Education Program at the University of Toronto.
Dr. Ronnie Hershman, M.D., F.C.C.S., Director
• Graduated Magna Cum Laude from Sophie Davis Center for Biomedical Research in 1980.
• Practicing Cardiologist since 1987 and Medical Director of NYU Langone Long island Cardiac Care.
• Pioneer in performing laser assisted coronary angioplasty
• Entrepreneur and investor for more than two decades and director and/or officer of over 9 life science companies.
• Track record of investing in companies that commercialize technologies quickly and globally
• Advisor to late stage life science VC that has funded 24 companies
Loran Swanberg, Director
• Part owner and a director of a private company, Landsman Properties Ltd. since 2005. Landsman owns and leases out shop and office
space in North East British Columbia and Alberta.
• From 1992 to 2005, Mr. Swanberg was a director of the family owned oilfield transportation company, Swanberg Bros. Trucking L td., which
was purchased by Producers Oilfield Services Inc. in 2005.
• Director of privately held Swanberg Air Inc. from 2000 to 2012, and was a director of the Northern B.C. Truckers' Association for 10 years,
1992 to 2002.
• Most recently, Mr. Swanberg was a partner and director of Vieworx Geophoto Inc. from 2012 until Q1 2020.
Thomas Smeenk, BA, President, CEO, Co-Founder & Director
• Founder, President and VP Business Development, TheraVitae Inc., which went public as Hemostemix Inc. QT.
• A finance and business development executive with a proven track record of bringing new discoveries to market.
• A public company executive since 1996, serving most recently as President & CEO of Broadway Gold Mining Ltd, where he complet ed a $30
million agreement with Rio Tinto. Prior, VP Business Development, Memex Inc.; President & CEO of e -Manufacturing Networks Inc.;
President and CEO of Tyranex Gold Inc. and President and CEO of IBI Corporation.
Christina Wu, CPA, CGA, Interim Chief Financial Officer
• Senior Financial Analyst employed by Marrelli Support Services Inc., a leader in providing financial accounting and reporting services to
• companies active in Canadian capital markets. Previously thereto, she was a Senior Associate with RSM Canada LLP.
• Graduated from the University of Guelph with a Bachelors of Commerce in Management Economics in 2007.
• Received her CPA, CGA designations in 2015.A D VIS ORY B OA R D
Timothy Chang, BA
• Currently a Private Investor and an investment committee member of an Asian-based hedge fund with average total AUM of
approximately US$1 billion. He has also been a consultant to Newport Healthcare Advisors and to SSG Capital Management. Mr.
Chang is a renowned private equity investor who has a track record of successful special situations and venture capital business
investments throughout the Asian region.
• Prior to becoming a Private Investor, he was a Managing Director of Citigroup Venture Capital International Asia Ltd., (CVCI) Hong Kong,
2005 – 2008, where he worked on and invested in private equity deals throughout Asia with a focus on Greater China. Prior to CVCI,
from 2003 – 2005, Mr. Chang was Managing Director and Head of Greater China for Cerberus, a distressed assets private equity fund
based in New York. Mr. Chang was also an Executive Director, Direct Investments and the Head of the Special Situations Group at AIG
Investment Corp. Ltd., Hong Kong.
• Graduated Harvard University, Cambridge, MA, Summa Cum Laude with a B.A. in Applied Mathematics and Economics. He completed
his senior honors thesis (with Professor Jeffrey Sachs as his thesis advisor) researching and modeling the Predictability of Realignments
in the European Monetary System.
David H. Tsubouchi, B.A., J.D., LL.D., D.S.Litt., C.Dir.
• David Tsubouchi is the first Japanese Canadian to be elected to any provincial legislature in Canada and to be appointed as a Cabinet
Minister. He has served as the Minister of Consumer and Commercial Relations, Solicitor General, Chair of Management Board and
Minister of Culture.
• Mr. Tsubouchi sits on the boards of OMERS Pension Fund, Lakefront Utilities and the Ontario Arts Council.
• He has previously served as the Honourary Consul General of Mongolia. As the former Registrar and CEO of the Ontario College of
Trades he oversaw the regulation of the skilled trades in Ontario. He has also served as the Integrity Commissioner for the Town of
Richmond Hill.
• His book, Gambatte was nominated for the Speaker’s Book Award and the Heritage Toronto Book Award.
Honorable Shelia Copps, OC, PC
• Former Deputy Prime Minister of Canada, Minister of Environment, Minister of Heritage and a senior member of the federal cabinet for 10
years.
• From her work on diversity and inclusion, to protection of the environment, to support for young Canadians and women, Sheila has had a
storied career that has left an indelible mark on Canadian public policy.
• Sheila brought forward what was the strongest federal environmental assessment legislation in the world; established Young Canada
Works to provide annual summer employment for youth; brought in copyright protection for Canadian recording artists; and led ministers
of culture from over 50 nations in the development of the first ever International Network on Cultural Diversity.
• Earned a Bachelor of Arts (Honors) in French and English from the University of Western Ontario in London and pursued further studies
at McMaster University in Hamilton and the University of Rouen in France. In 1998, received an Honorary Doctorate in Law from
Université Sainte-Anne in Nova Scotia in recognition of her efforts to promote bilingualism and her commitment to advancing the French
language and culture in Canada.
• In recent years, she has been working both in French and English as a journalist, broadcaster, and political commentator. She is the
author of two books, Nobody’s Baby and Worth Fighting For.S C IE NT IF IC A D VIS ORY B OA R D
Dr. York Hsiang, MB, ChB, MHSc, FRCSC
• Professor of Vascular Surgery at University of British Columbia, and Consultant Surgeon at the Vancouver General Hospital
• Dr. Hsiang has diverse interests in vascular biology, vascular engineering and clinical epidemiology. He is the past Presiden t of the Chinese-
Canadian Medical Society and the Western Vascular Society.
• Written or co-written and presented 165 continuing medical education accredited papers to peers at regional, national and intern ational
symposia focused on such diverse topics as a pressure-sensing smart stent compatible with angioplasty procedure and its in vivo testing;
vascular surgery; advanced venous issues; carotid surgery; and, he presented the Company’s blinded results to the 41st annual meeting of
the Canadian Society for Vascular Surgery, held September 13-14, 2019
Dr. Pierre Leimgruber, MD, FACC
• Board-certified in internal medicine, cardiovascular diseases, and interventional cardiology. Specialist in cardiovascular dise ase treatment.
• He has worked for 32 years as an interventional cardiologist, affiliated with four leading Spokane hospitals and also serves as Clinical
Associate Professor of Medicine at the University of Washington School of Medicine in Seattle.
• Received his medical degree from University of Zurich Medical School and trained with Andreas Gruentzig, MD, the inventor of balloon
angioplasty, at Emory University Hospital in Atlanta.
• Author of 26 peer-reviewed research studies published in leading medical journals.
Dr. Alan B. Lumsden, M.D.
• Walter W. Fondren III Chair, Medical Director of the Houston Methodist DeBakey Heart and Vascular Center and chair of the Department of
Cardiovascular Surgery at Houston Methodist Hospital since 2008
• Emory University (Atlanta)-completed his surgical residency and vascular training leading to position as Chief of Division of Va scular Surgery
• International reputation as a leader in the field of endovascular surgery. He conducts FDA-mandated training for surgeons nationwide and
has received millions of dollars for his research from the National Institutes of Health. He has contributed more than 200 papers to medical
literature.
Dr. Norman C. W. Wong, B.Sc (Hon), M.Sc, M.D., FRCP(C)
• Co-Founder of Resverlogix Corp. (TSX:RVX), and Chief Scientific Officer since 2003
• Currently Professor of Medicine and Biochemistry & Molecular Biology and Director of the Libin Gene/Cell Therapy Unit within the Faculty of
Medicine at the University of Calgary
• Specializes in the areas of Endocrinology, Internal Medicine, Molecular Biology and Gene/Cell Therapy
• Author &/or co-author of over 275 articles and abstracts and invited to sit on more than 40 national or international panels/ committees
• Consulted for leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott
Laboratories
Dr. Kumar L. Hari, PhD
• Chief Scientific Officer at cBio, a private disease diagnostics and tracking firm
• Expertise is in chromosome biology, functional genomics, and bioinformatics. Oversaw the development of the MRS and PATRN pla tforms
• At cBio, Dr. Hari led the team in engagements with the FDA, various universities and other US government organizations
• Former director of program management efforts the California Institute of Regenerative Medicine and the Myelin Repair Foundat ion
• PhD in Cell Biology from UC San Diego and a B.Sc. in Genetics from UC DavisS H A R E C A P ITA L O V E RV IE W
Share capital structure as of December 31, 2020
($CAD)
Number Ex. Price Expiry or Closing
Common Shares Issued and Outstanding 55,535,638
Stock Options 5,342,000 $0.70-$2.00 Apr 2023-Dec 2025
Share Purchase Warrants² 39,241,348 $1.00 Mar 2021-Dec 2021
Finder Warrants (See note 1 below) 1,859,290 $0.20-$1.00 Mar 2021-Dec 2021
Fully Diluted¹ (Includes dilutive effect of 2 x finder warrants) 103,837,566¹
¹Includes 1,859,290 finder w arrants which are exercisable into Units (one share and one w arrant; totaling 1,859,290 shares and 1,859,290 w arrants).
²Share Purchase Warrants – (each warrant exercisable into a share)
Number Ex. Price Expiry
13,618,522 $1.00 Mar 5-Mar 25, 2021
9,177,125 $1.00 May 7-July 9, 2021
918,450 $1.00 Nov 24, 2021
15,527,251 $1.00 Dec 18-Dec 25, 2021P E R S O N AL I Z E D S T E M C E L L T H E R AP Y T O D AY
WO R L D E C O N O M I C F O R U M T E C H N O L OG Y P I O N E E R , 2006
Shaping
The Future
of Medicine For more Information please contact:
Thomas A. Smeenk www.hemostemix.com
President and CEO Suite 1150, 707-7th Avenue SW
905-580-4170 Calgary, AB T2P 3H6
TSXV:HEM OTC:HMTXFRIGHTS OF ACTION FOR DAMAGES OR RESCISSION The following statutory rights of action for damages or rescission will only apply to a purchaser of securities of the Company in the event that this presentation is deemed to be an offering memorandum pursuant to applicable securities legislation in certain provinces of Canada. These remedies, or notice with respect thereto, must be exercised, or delivered, as the case may be, by the purchaser within the time limits prescribed by the applicable provisions of the provincial securities legislation. Purchasers should refer to the applicable securities legislation for the complete text of these rights or consult with a legal adviser. Where used in this section, “Misrepresentation” means an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made. Ontario Securities legislation in Ontario provides that purchasers of securities are entitled to rights of action for rescission or damages where an offering memorandum and any amendment to it contains a Misrepresentation. In accordance with Section 130.1 of the Securities Act (Ontario) (the “Ontario Act”), in the event that an offering memorandum or any amendment thereto contains a Misrepresentation, a purchaser who purchases securities offered by such offering memorandum during the period of distribution has, without regard to whether the purchaser relied upon the Misrepresentation, a right of action against the issuer for damages, or, while still the owner of the such securities purchased by that purchaser, for rescission, in which case, if the purchaser elects to exercise the right of rescission, the purchaser will have no right of action for damages against the issuer, provided that: (a) the issuer will not be liable if it proves that the purchaser purchased the securities with knowledge of the Misrepresentation; (b) in the case of an action for damages, the issuer will not be liable for all or any portion of the damages that it proves do not represent the depreciation in value of the securities as a result of the Misrepresentation relied upon; and (c) in no case will the amount recoverable in any action exceed the price at which the securities were sold to the purchaser. A purchaser resident in Ontario should refer to the provisions of the Ontario Act and its regulations for particulars of the rights and defences discussed above and consult with a lawyer. The rights discussed above are in addition to and without derogation from any other right or remedy which a purchaser might have at law. No action shall be commenced to enforce these statutory rights more than: (a) in an action for rescission, 180 days from the date of the transaction that gave rise to the cause of action; or (b) in an action for damages, the earlier of: (i) 180 days after the plaintiff first had knowledge of the facts giving rise to the cause of action; or (ii) three years after the date of the transaction that gave rise to the cause of action.
You can also read
